TETERBORO, N.J., Sept. 7 /PRNewswire-FirstCall/ -- Quest Diagnostics
Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing,
information and services, announced that Robert A. Hagemann, Senior Vice
President and Chief Financial Officer, is scheduled to speak at the Thomas
Weisel Partners Tailwinds Conference on Wednesday, September 8, 2004, at The
Four Seasons Hotel in Boston, Massachusetts. The Quest Diagnostics
presentation is scheduled to begin at 8:00 a.m. Eastern Time.
During the conference the company will reiterate its third quarter 2004
guidance of approximately 6% revenue growth, operating income to exceed 18% of
revenues, and earnings per diluted share between $1.25 and $1.30. This
guidance does not include the impact from the recent hurricanes in Florida,
which will take some time for the company to fully assess.
The presentation will be webcast live during the conference and will be
available to registered investors on the following site:
http://www.visualwebcaster.com/event.asp?id=24279 and to the public on
http://www.questdiagnostics.com. In addition, the archived webcast will be
available starting two hours after the presentation.
Quest Diagnostics Incorporated is the nation's leading provider of
diagnostic testing, information and services, providing insights that enable
healthcare professionals to make decisions that improve health. The company
offers the broadest access to diagnostic testing services through its national
network of laboratories and patient service centers, and provides interpretive
consultation through its extensive medical and scientific staff. Quest
Diagnostics is the leading provider of esoteric testing, including gene-based
medical testing, and provides advanced information technology solutions to
improve patient care. Additional company information is available at:
http://www.questdiagnostics.com.
The statements in this press release which are not historical facts or
information may be forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause actual results and
outcomes to be materially different. Certain of these risks and uncertainties
may include, but are not limited to, competitive environment, changes in
government regulations, changing relationships with customers, payers,
suppliers and strategic partners and other factors described in the Quest
Diagnostics Incorporated 2003 Form 10-K and subsequent filings.
SOURCE Quest Diagnostics Incorporated
-0- 09/07/2004
/CONTACT: Investors, Laure Park, +1-201-393-5030, or Media, Jennifer
Somers, +1-201-393-5700, both of Quest Diagnostics/
/Web site: http://www.questdiagnostics.com
http://www.visualwebcaster.com/event.asp?id=24279 /
(DGX)